The Trouble with Spin-Offs

01 Sep 2004

• By Michael Lytton

Drug firms have created relatively few venture-financed spin-offs. The central reason--the valuation impasse between VC and pharma--is as much pscyhologically rooted as financially.

Q: Why are there relatively few venture-financed spin-offs from pharmaceutical companies, despite the apparent attractiveness of this type of transaction to both venture funds and pharma companies?

A: Not for lack of trying by parties on both sides of these proposed transactions. Yet few of these deals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

22 Jul 2025

• By Mandy Jackson

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

22 Jul 2025

• By Joseph Haas

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.